BIOMAT Database Logo BIOMAT Database Logo

Weekly CODE chemotherapy with recombinant human granulocyte colony-stimulating factor for relapsed or refractory small cell lung cancer. 2000

K Sato, and S Tsuchiya, and K Minato, and N Sunaga, and S I Ishihara, and T Makimoto, and I Naruse, and H Hoshino, and S Watanabe, and R Saitoh, and M Mori
Department of Internal Medicine, National Nishi-Gunma Hospital, Shibukawa, Gunma 377-8511, Japan. satouk@nngh.hosp.go.jp

We used cisplatin, vincristine, doxorubicin, and etoposide (CODE) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) weekly for salvage chemotherapy in relapsed or refractory small cell lung cancer (SCLC). We reviewed the medical charts of patients between January 1993 and December 1996 at the National Nishi-Gunma Hospital. Twenty patients were treated with salvage chemotherapy. The overall response rate was 55.0%. The median survival time of extensive disease patients from the start of CODE therapy was 23 weeks and the 1-year survival rate was 21.0%. Toxicities were severe, especially in myelosuppression. CODE could be selected as a salvage therapy for chemotherapy- relapsed SCLC cases.

UI MeSH Term Description Entries
D007970 Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). Leukocytopenia,Leukocytopenias,Leukopenias
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females

Related Publications

K Sato, and S Tsuchiya, and K Minato, and N Sunaga, and S I Ishihara, and T Makimoto, and I Naruse, and H Hoshino, and S Watanabe, and R Saitoh, and M Mori
CODE chemotherapy with or without recombinant human granulocyte colony-stimulating factor in extensive-stage small cell lung cancer.
January 1992, Oncology,
K Sato, and S Tsuchiya, and K Minato, and N Sunaga, and S I Ishihara, and T Makimoto, and I Naruse, and H Hoshino, and S Watanabe, and R Saitoh, and M Mori
CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.
January 1997, British journal of cancer,
K Sato, and S Tsuchiya, and K Minato, and N Sunaga, and S I Ishihara, and T Makimoto, and I Naruse, and H Hoshino, and S Watanabe, and R Saitoh, and M Mori
Recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for non-small cell lung cancer.
January 1993, European journal of cancer (Oxford, England : 1990),
K Sato, and S Tsuchiya, and K Minato, and N Sunaga, and S I Ishihara, and T Makimoto, and I Naruse, and H Hoshino, and S Watanabe, and R Saitoh, and M Mori
Efficacy of recombinant human granulocyte-macrophage colony-stimulating factor for chemotherapy-induced leukopenia in patients with non-small-cell lung cancer.
January 1994, Cancer chemotherapy and pharmacology,
K Sato, and S Tsuchiya, and K Minato, and N Sunaga, and S I Ishihara, and T Makimoto, and I Naruse, and H Hoshino, and S Watanabe, and R Saitoh, and M Mori
Ifosfamide, cisplatin and etoposide (ICE) combined chemotherapy with recombinant human granulocyte colony-stimulating factor support in small cell lung cancer.
February 1997, Journal of chemotherapy (Florence, Italy),
K Sato, and S Tsuchiya, and K Minato, and N Sunaga, and S I Ishihara, and T Makimoto, and I Naruse, and H Hoshino, and S Watanabe, and R Saitoh, and M Mori
Infection risk in patients with small cell lung cancer receiving intensive chemotherapy and recombinant human granulocyte-macrophage colony-stimulating factor.
January 1992, European journal of cancer (Oxford, England : 1990),
K Sato, and S Tsuchiya, and K Minato, and N Sunaga, and S I Ishihara, and T Makimoto, and I Naruse, and H Hoshino, and S Watanabe, and R Saitoh, and M Mori
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.
August 1988, Behring Institute Mitteilungen,
K Sato, and S Tsuchiya, and K Minato, and N Sunaga, and S I Ishihara, and T Makimoto, and I Naruse, and H Hoshino, and S Watanabe, and R Saitoh, and M Mori
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.
December 1987, British journal of cancer,
K Sato, and S Tsuchiya, and K Minato, and N Sunaga, and S I Ishihara, and T Makimoto, and I Naruse, and H Hoshino, and S Watanabe, and R Saitoh, and M Mori
Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
June 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
K Sato, and S Tsuchiya, and K Minato, and N Sunaga, and S I Ishihara, and T Makimoto, and I Naruse, and H Hoshino, and S Watanabe, and R Saitoh, and M Mori
Pegylated recombinant human granulocyte colony-stimulating factor regulates the immune status of patients with small cell lung cancer.
March 2020, Thoracic cancer,
Copied contents to your clipboard!